With the development of material science, a liposomal nanoparticles loaded dsRNAs named MTL‐CEBPA had been successfully delivered to rat liver and suppressed tumorigenesis of rat hepatocellular carcinoma model via activating CEBPA expression, and the MTL‐CEBPA is now in a phase I clinical trial for patients with advanced cirrhotic hepatocellular carcinoma.20 This evidence concerns the gene CEBPA and hepatocellular carcinoma.